Effects of bile acids on neurological function and disease

FASEB Journal

Volumn 30, Issue 11, 2016, Pages 3658-3668

  McMillin, Matthew ^a,b   DeMorrow, Sharon ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cholesterol; FXR; Metabolism; Neuroinflammation; TGR5

Indexed keywords

4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; 4 AMINOBUTYRIC ACID; BILE ACID; CELL NUCLEUS RECEPTOR; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLESTYRAMINE; CYTOCHROME P450; CYTOCHROME P450 46A1; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTULOSE; MEMBRANE RECEPTOR; METRONIDAZOLE; N METHYL DEXTRO ASPARTIC ACID; NEOMYCIN; OBETICHOLIC ACID; PRAVASTATIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; TAKEDA G PROTEIN COUPLED RECEPTOR 5; TAURODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN; VERY LATE ACTIVATION ANTIGEN 5; CELL RECEPTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BRAIN; CEREBROTENDINOUS XANTHOMATOSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL METABOLISM; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; LIVER; METABOLITE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NERVOUS SYSTEM FUNCTION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPATHY; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY; ANIMAL; HOMEOSTASIS; METABOLISM; PHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTEROL; HOMEOSTASIS; HUMANS; LIVER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84995546455     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201600275R     Document Type: Review

References (100)

1. Dawson, P. A., Lan, T., and Rao, A. (2009) Bile acid transporters. J. Lipid Res. 50, 2340-2357
2. Lorbek, G., Lewinska, M., and Rozman, D. (2012) Cytochrome P450s in the synthesis of cholesterol and bile acids: from mouse models to human diseases. FEBS J. 279, 1516-1533
3. Lund, E. G., Guileyardo, J. M., and Russell, D. W. (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc.Natl. Acad. Sci. USA 96, 7238-7243
4. Russell, D. W. (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174
5. Uno, Y., Hosaka, S., and Yamazaki, H. (2014) Identification and analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in cynomolgus macaques. J. Vet. Med. Sci. 76, 1647-1650
6. Ishibashi, S., Schwarz, M., Frykman, P. K., Herz, J., and Russell, D. W. (1996)Disruptionof cholesterol 7alpha-hydroxylase gene inmice: I, postnatal lethality reversed by bile acid and vitamin supplementation. J. Biol. Chem. 271, 18017-18023
7. Schwarz, M., Lund, E. G., Setchell, K.D., Kayden, H. J., Zerwekh, J.E., Björkhem, I., Herz, J., and Russell, D. W. (1996) Disruption of cholesterol 7alpha-hydroxylase gene inmice: II, bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J. Biol. Chem. 271, 18024-18031
8. Erickson, S.K., Lear, S.R., Deane, S., Dubrac, S., Huling, S.L., Nguyen, L., Bollineni, J. S., Shefer, S., Hyogo, H., Cohen, D. E., Shneider, B., Sehayek, E., Ananthanarayanan, M., Balasubramaniyan, N., Suchy, F. J., Batta, A. K., and Salen, G. (2003) Hypercholesterolemia and changes in lipid and bile acidmetabolisminmale and female cyp7A1-deficient mice. J. Lipid Res. 44, 1001-1009
9. Pullinger, C.R., Eng, C., Salen, G., Shefer, S., Batta, A.K., Erickson, S.K., Verhagen, A., Rivera, C. R., Mulvihill, S. J., Malloy, M. J., and Kane, J. P. (2002) Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109-117
10. Kim, H. J., Park, H. Y., Kim, E., Lee, K. S., Kim, K. K., Choi, B.O., Kim, S.M., Bae, J.S., Lee, S.O., Chun, J. Y., Park, T. J., Cheong, H. S., Jo, I., and Shin, H. D. (2010) Common CYP7A1 promoter polymorphism associated withrisk of neuromyelitis optica. Neurobiol. Dis. 37, 349-355
11. Rosen, H., Reshef, A., Maeda, N., Lippoldt, A., Shpizen, S., Triger, L., Eggertsen, G., Björkhem, I., and Leitersdorf, E. (1998) Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J. Biol. Chem. 273, 14805-14812
12. Repa, J. J., Lund, E. G., Horton, J. D., Leitersdorf, E., Russell, D. W., Dietschy, J.M., and Turley, S. D. (2000) Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia: reversal by cholic acid feeding. J. Biol. Chem. 275, 39685-39692
13. Bavner, A., Shafaati, M., Hansson, M., Olin, M., Shpitzen, S., Meiner, V., Leitersdorf, E., and Björkhem, I. (2010) On the mechanism of accumulation of cholestanol inthe brain ofmicewith a disruption of sterol 27-hydroxylase. J. Lipid Res. 51, 2722-2730
14. Nie, S., Chen, G., Cao, X., and Zhang, Y. (2014) Cerebrotendinous xanthomatosis: A comprehensive review of pathogenesis, clinical manifestations, diagnosis, andmanagement. Orphanet J. Rare Dis. 9, 179
15. Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., and Russell, D. W. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 22980-22988
16. Kotti, T. J., Ramirez, D. M., Pfeiffer, B. E., Huber, K. M., and Russell, D. W. (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. USA 103, 3869-3874
17. Hofmann, A. F. (1999) The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159, 2647-2658
18. Wang, H., Chen, J., Hollister, K., Sowers, L. C., and Forman, B. M. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3, 543-553
19. Dawson, P. A. (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb. Exp. Pharmacol. 201, 169-203
20. Ding, L., Yang, L., Wang, Z., and Huang, W. (2015) Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm. Sin. B 5, 135-144
21. Calkin, A.C., andTontonoz, P. (2012)Transcriptional integrationof metabolismby the nuclear sterol-Activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 13, 213-224
22. Bookout, A. L., Jeong, Y., Downes, M., Yu, R. T., Evans, R. M., and Mangelsdorf, D. J. (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126, 789-799
23. McMillin, M., Frampton, G., Quinn, M., Ashfaq, S., de los Santos III, M., Grant, S., andDeMorrow, S. (2016) Bile acid signaling is involved in the neurological decline in a murine model of acute liver failure. Am. J. Pathol. 186, 312-323
24. Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., and Tanaka, K. (2002) Identification of membrane-Type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719
25. Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., Hinuma, S., Fujisawa, Y., and Fujino, M. (2003) A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435-9440
26. Keitel, V., Görg, B., Bidmon, H. J., Zemtsova, I., Spomer, L., Zilles, K., and Häussinger, D. (2010) The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 58, 1794-1805
27. McMillin, M., Frampton, G., Tobin, R., Dusio, G., Smith, J., Shin, H., Newell-Rogers, K., Grant, S., andDeMorrow, S. (2015)TGR5 signaling reduces neuroinflammation during hepatic encephalopathy. J. Neurochem. 135, 565-576
28. Vassileva, G., Golovko, A., Markowitz, L., Abbondanzo, S. J., Zeng, M., Yang, S., Hoos, L., Tetzloff, G., Levitan, D., Murgolo, N. J., Keane, K., Davis, H. R., Jr., Hedrick, J., andGustafson, E. L. (2006) Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem. J. 398, 423-430
29. Pols, T. W., Nomura, M., Harach, T., Lo Sasso, G., Oosterveer, M.H., Thomas, C., Rizzo, G., Gioiello, A., Adorini, L., Pellicciari, R., Auwerx, J., and Schoonjans, K. (2011) TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14, 747-757
30. Yang, A. H., Ishii, I., and Chun, J. (2002) In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim. Biophys. Acta 1582, 197-203
31. Studer, E., Zhou, X., Zhao, R., Wang, Y., Takabe, K., Nagahashi, M., Pandak, W.M., Dent, P., Spiegel, S., Shi, R., Xu, W., Liu, X., Bohdan, P., Zhang, L., Zhou, H., and Hylemon, P. B. (2012) Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 55, 267-276
32. Kageyama, Y., Ikeda, H., Watanabe, N., Nagamine, M., Kusumoto, Y., Yashiro, M., Satoh, Y., Shimosawa, T., Shinozaki, K., Tomiya, T., Inoue, Y., Nishikawa, T., Ohtomo, N., Tanoue, Y., Yokota, H., Koyama, T., Ishimaru, K., Okamoto, Y., Takuwa, Y., Koike, K., and Yatomi, Y. (2012) Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile ductligated rodents. Hepatology 56, 1427-1438
33. MacLennan, A. J., Carney, P. R., Zhu, W. J., Chaves, A. H., Garcia, J., Grimes, J. R., Anderson, K. J., Roper, S. N., and Lee, N. (2001) An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur. J. Neurosci. 14, 203-209
34. Toman, R. E., Payne, S. G., Watterson, K.R., Maceyka, M., Lee, N.H., Milstien, S., Bigbee, J. W., and Spiegel, S. (2004) Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J. Cell Biol. 166, 381-392
35. Marchetti, G., Escuin, S., van der Flier, A., De Arcangelis, A., Hynes, R. O., and Georges-Labouesse, E. (2010) Integrin alpha5beta1 is necessary for regulation of radial migration of cortical neurons during mouse brain development. Eur. J. Neurosci. 31, 399-409
36. Tonge, D.A., de Burgh, H.T., Docherty, R., Humphries, M. J., Craig, S. E., and Pizzey, J. (2012) Fibronectin supports neurite outgrowth and axonal regeneration of adult brain neurons in vitro. Brain Res. 1453, 8-16
37. Roberts, J., de Hoog, L., and Bix, G. J. (2015) Mice deficient in endothelial a5 integrin are profoundly resistant to experimental ischemic stroke. J. Cereb. Blood Flow Metab. 0271678X15616979
38. Gohlke, H., Schmitz, B., Sommerfeld, A., Reinehr, R., and Häussinger, D. (2013) a5 b1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology 57, 1117-1129
39. Lehmann, J.M., McKee, D. D., Watson, M. A., Willson, T.M., Moore, J. T., and Kliewer, S. A. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023
40. Staudinger, J. L., Goodwin, B., Jones, S. A., Hawkins-Brown, D., MacKenzie, K. I., LaTour, A., Liu, Y., Klaassen, C. D., Brown, K. K., Reinhard, J., Willson, T. M., Koller, B. H., and Kliewer, S. A. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc.Natl. Acad. Sci. USA 98, 3369-3374
41. Litwa, E., Rzemieniec, J., Wnuk, A., Lason, W., Krzeptowski, W., and Kajta, M. (2016)RXRa, PXRandCARxenobiotic receptorsmediate the apoptotic and neurotoxic actions of nonylphenol in mouse hippocampal cells. J. Steroid Biochem. Mol. Biol. 156, 43-52
42. Frye, C. A., Koonce, C. J., and Walf, A. A. (2014) The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats. Front. Syst. Neurosci. 8, 60
43. Norman, A. W. (2006) Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147, 5542-5548
44. Adachi, R., Shulman, A. I., Yamamoto, K., Shimomura, I., Yamada, S., Mangelsdorf, D. J., and Makishima, M. (2004) Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol. Endocrinol. 18, 43-52
45. Jurutka, P. W., Thompson, P. D., Whitfield, G. K., Eichhorst, K. R., Hall, N., Dominguez, C.E., Hsieh, J. C., Haussler, C.A., andHaussler, M. R. (2005) Molecular and functional comparison of 1, 25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. J. Cell. Biochem. 94, 917-943
46. Schmidt, D. R., Holmstrom, S. R., Fon Tacer, K., Bookout, A. L., Kliewer, S. A., andMangelsdorf, D. J. (2010) Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 285, 14486-14494
47. Jang, W., Park, H.H., Lee, K. Y., Lee, Y. J., Kim, H. T., andKoh, S. H. (2015) 1, 25-dyhydroxyvitamin D3 attenuates L-DOPA-induced neurotoxicity in neural stem cells. Mol. Neurobiol. 51, 558-570
48. Durk, M. R., Han, K., Chow, E. C., Ahrens, R., Henderson, J. T., Fraser, P. E., and Pang, K. S. (2014) 1a, 25-Dihydroxyvitamin D3 reduces cerebral amyloid-b accumulationandimproves cognitionin mouse models of Alzheimer's disease. J. Neurosci. 34, 7091-7101
49. Chang, T. K. (2009) Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 11, 590-601
50. Lamba, J.K., Lamba, V., Yasuda, K., Lin, Y. S., Assem, M., Thompson, E., Strom, S., and Schuetz, E. (2004) Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J. Pharmacol. Exp. Ther. 311, 811-821
51. Beilke, L. D., Aleksunes, L. M., Holland, R. D., Besselsen, D. G., Beger, R. D., Klaassen, C. D., and Cherrington, N. J. (2009) Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection fromlithocholic acidinduced liver injury in mice. Drug Metab. Dispos. 37, 1035-1045
52. Lemmen, J., Tozakidis, I. E., Bele, P., and Galla, H. J. (2013) Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the blood-brain barrier after CITCO activation. Brain Res. 1501, 68-80
53. Schweingruber, N., Reichardt, S. D., Lühder, F., and Reichardt, H. M. (2012) Mechanisms of glucocorticoids in the control of neuroinflammation. J. Neuroendocrinol. 24, 174-182
54. Sun, X.C., Ren, X.F., Chen, L., Gao, X.Q., Xie, J. X., andChen, W.F. (2016) Glucocorticoid receptor is involved in the neuroprotective effect of ginsenoside Rg1 against inflammation-induced dopaminergic neuronal degeneration in substantia nigra. J. Steroid Biochem. Mol. Biol. 155(Pt A), 94-103
55. Takigawa, T., Miyazaki, H., Kinoshita, M., Kawarabayashi, N., Nishiyama, K., Hatsuse, K., Ono, S., Saitoh, D., Seki, S., and Yamamoto, J. (2013) Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G427-G438
56. McMillin, M., Frampton, G., Quinn, M., Divan, A., Grant, S., Patel, N., Newell-Rogers, K., and DeMorrow, S. (2015) Suppression of the HPA axis during cholestasis can be attributed to hypothalamic bile acid signaling. Mol. Endocrinol. 29, 1720-1730
57. Naqvi, S. H., Herndon, B. L., Kelley, M. T., Bleisch, V., Aexel, R. T., andNicholas, H. J. (1969) Detection ofmonohydroxy "bile" acids in the brains of guinea pigs afflicted with experimental allergic encephalomyelitis. J. Lipid Res. 10, 115-120
58. Mujtaba Naqvi, S. H., and Nicholas, H. J. (1970) Conversion of 3-keto-5-beta-cholanoic acid to lithocholic acid by guinea pig brain tissue, in vitro. Steroids 16, 297-316
59. Mano, N., Goto, T., Uchida, M., Nishimura, K., Ando, M., Kobayashi, N., and Goto, J. (2004) Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain. J. Lipid Res. 45, 295-300
60. Bron, B., Waldram, R., Silk, D. B., and Williams, R. (1977) Serum, cerebrospinal fluid, and brain levels of bile acids in patients with fulminant hepatic failure. Gut 18, 692-696
61. Schubring, S. R., Fleischer, W., Lin, J. S., Haas, H. L., and Sergeeva, O. A. (2012) The bile steroid chenodeoxycholate is a potent antagonist at NMDA and GABA(A) receptors. Neurosci. Lett. 506, 322-326
62. Yanovsky, Y., Schubring, S. R., Yao, Q., Zhao, Y., Li, S., May, A., Haas, H. L., Lin, J. S., and Sergeeva, O. A. (2012) Waking action of ursodeoxycholic acid (UDCA) involves histamine and GABAA receptor block. PLoS One 7, e42512
63. Zhao, C., Wang, X., Cong, Y., Deng, Y., Xu, Y., Chen, A., and Yin, Y. (2014)Effectsof bile acids and the bile acid receptor FXRagoniston the respiratory rhythm in the in vitro brainstem medulla slice of neonatal Sprague-Dawley rats. PLoS One 9, e112212
64. Huang, F., Wang, T., Lan, Y., Yang, L., Pan, W., Zhu, Y., Lv, B., Wei, Y., Shi, H., Wu, H., Zhang, B., Wang, J., Duan, X., Hu, Z., and Wu, X. (2015) Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior. Front. Behav. Neurosci. 9, 70
65. McNeilly, A. D., Macfarlane, D. P., O'Flaherty, E., Livingstone, D. E., Mitíc, T., McConnell, K. M., McKenzie, S. M., Davies, E., Reynolds, R. M., Thiesson, H. C., Skøtt, O., Walker, B. R., and Andrew, R. (2010) Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-Adrenal axis in obstructive jaundice. J. Hepatol. 52, 705-711
66. Quinn, M., Ueno, Y., Pae, H. Y., Huang, L., Frampton, G., Galindo, C., Francis, H., Horvat, D., McMillin, M., and Demorrow, S. (2012) Suppression of theHPA axis during extrahepatic biliary obstruction induces cholangiocyte proliferation in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G182-G193
67. Swain, M. G., Patchev, V., Vergalla, J., Chrousos, G., and Jones, E. A. (1993) Suppression of hypothalamic-pituitary-Adrenal axis responsiveness to stress ina ratmodel of acute cholestasis. J. Clin. Invest. 91, 1903-1908
68. Quinn, M., McMillin, M., Galindo, C., Frampton, G., Pae, H. Y., and DeMorrow, S. (2014)Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig. Liver Dis. 46, 527-534
69. Theofilopoulos, S., Wang, Y., Kitambi, S. S., Sacchetti, P., Sousa, K. M., Bodin, K., Kirk, J., Salto, C., Gustafsson, M., Toledo, E. M., Karu, K., Gustafsson, J. A., Steffensen, K. R., Ernfors, P., Sjövall, J., Griffiths, W. J., and Arenas, E. (2013) Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat. Chem. Biol. 9, 126-133
70. Cash, W. J., McConville, P., McDermott, E., McCormick, P. A., Callender, M. E., and McDougall, N. I. (2010) Current concepts in the assessment and treatment of hepatic encephalopathy. QJM 103, 9-16
71. Butterworth, R. F. (2013) The liver-brain axis in liver failure: neuroinflammation and encephalopathy.Nat.Rev.Gastroenterol.Hepatol. 10, 522-528
72. Tripodi, V., Contin, M., Ferńandez, M. A., and Lemberg, A. (2012) Bile acids content in brain of common duct ligated rats.Ann. Hepatol. 11, 930-934
73. Lorincz, M. T., Rainier, S., Thomas, D., and Fink, J. K. (2005) Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch. Neurol. 62, 1459-1463
74. Björkhem, I., and Hansson, M. (2010) Cerebrotendinous xanthomatosis: An inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 396, 46-49
75. Ginanneschi, F., Mignarri, A., Mondelli, M., Gallus, G. N., Del Puppo, M., Giorgi, S., Federico, A., Rossi, A., and Dotti, M. T. (2013) Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J. Neurol. 260, 268-274
76. Pilo-de-la-Fuente, B., Jimenez-Escrig, A., Lorenzo, J. R., Pardo, J., Arias, M., Ares-Luque, A., Duarte, J., Muñiz-Ṕerez, S., and Sobrido, M. J. (2011) Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur. J. Neurol. 18, 1203-1211
77. Kuriyama, M., Tokimura, Y., Fujiyama, J., Utatsu, Y., and Osame, M. (1994) Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J.Neurol. Sci. 125, 22-28
78. Mujtaba Naqvi, S. H., Ramsey, R. B., and Nicholas, H. J. (1970) Detection of lithocholic acid in multiple sclerosis brain tissue. Lipids 5, 578-580
79. Lewis, N. D., Patnaude, L. A., Pelletier, J., Souza, D. J., Lukas, S. M., King, F. J., Hill, J. D., Stefanopoulos, D.E., Ryan, K., Desai, S., Skow, D., Kauschke, S. G., Broermann, A., Kuzmich, D., Harcken, C., Hickey, E. R., and Modis, L. K. (2014) A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo. PLoS One 9, e100883
80. Ho, P. P., and Steinman, L. (2016) Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 113, 1600-1605
81. Selkoe, D. J., and Hardy, J. (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595-608
82. Rodrigues, C. M., Soĺa, S., Silva, R., and Brites, D. (2000) Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization. Mol. Med. 6, 936-946
83. Ramalho, R. M., Ribeiro, P. S., Soĺa, S., Castro, R. E., Steer, C. J., and Rodrigues, C. M. (2004) Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J. Neurochem. 90, 567-575
84. Nunes, A. F., Amaral, J. D., Lo, A. C., Fonseca, M. B., Viana, R. J., Callaerts-Vegh, Z., D'Hooge, R., andRodrigues, C.M. (2012)TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-b deposition in APP/PS1 mice. Mol. Neurobiol. 45, 440-454
85. Diońisio, P.A., Amaral, J.D., Ribeiro, M. F., Lo, A. C., D'Hooge, R., and Rodrigues, C.M. (2015) Amyloid-b pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol. Aging 36, 228-240
86. Zhang, J., Li, P., Wang, Y., Liu, J., Zhang, Z., Cheng, W., and Wang, Y. (2013) Ameliorative effects of a combination of baicalin, jasminoidin and cholic acid on ibotenic acid-induced dementia model in rats. PLoS One 8, e56658
87. Bonifati, V. (2006) Parkinson's disease: The LRRK2-G2019S mutation: opening anovel era in Parkinson's disease genetics. Eur. J.Hum. Genet. 14, 1061-1062
88. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., Ahmad, R., Miller, D.W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R. J., Harvey, K., and Cookson, M. R. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341
89. Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231-1233
90. Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., and Bandmann, O. (2015) UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology 85, 846-852
91. Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M., Alfonso, A., Steer, C., Liu, L., Przedborski, S., and Wolozin, B. (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280, 42655-42668
92. Kalsotra, A., Turman, C. M., Dash, P. K., and Strobel, H. W. (2003) Differential effectsof traumatic braininjury onthe cytochrome p450 system: A perspective into hepatic and renal drug metabolism. J. Neurotrauma 20, 1339-1350
93. Cheng, C. Y., Ho, C. H., Wang, C. C., Liang, F.W., Wang, J. J., Chio, C. C., Chang, C. H., and Kuo, J. R. (2015) One-year mortality after traumatic brain injury in liver cirrhosis patients: A ten-year population-based study. Medicine (Baltimore) 94, e1468
94. Raghupathi, R., Graham, D. I., andMcIntosh, T. K. (2000)Apoptosis after traumatic brain injury. J. Neurotrauma 17, 927-938
95. Ramalho, R.M., Borralho, P. M., Castro, R. E., Soĺa, S., Steer, C. J., and Rodrigues, C.M. (2006) Tauroursodeoxycholic acidmodulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J. Neurochem. 98, 1610-1618
96. Gaspar, J.M., Martins, A., Cruz, R., Rodrigues, C.M., Ambŕosio, A. F., and Santiago, A. R. (2013) Tauroursodeoxycholic acid protects retinal neural cells fromcell death induced by prolonged exposure to elevated glucose. Neuroscience 253, 380-388
97. Rodrigues, C. M., Spellman, S. R., Soĺa, S., Grande, A. W., Linehan-Stieers, C., Low, W. C., and Steer, C. J. (2002) Neuroprotection by a bile acid in an acute stroke model in the rat. J. Cereb. Blood Flow Metab. 22, 463-471
98. Rodrigues, C.M., Sola, S., Nan, Z., Castro, R. E., Ribeiro, P. S., Low, W. C., and Steer, C. J. (2003) Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc. Natl. Acad. Sci. USA 100, 6087-6092
99. Elia, A. E., Lalli, S., Monsurr'o, M. R., Sagnelli, A., Taiello, A. C., Reggiori, B., La Bella, V., Tedeschi, G., and Albanese, A. (2016) Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 23, 45-52
100. Vaz, A. R., Cunha, C., Gomes, C., Schmucki, N., Barbosa, M., and Brites, D. (2015) Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol. Neurobiol. 51, 864-877